Business Wire

SAMSUNG-SEMICONDUCTOR

15.9.2020 11:02:12 CEST | Business Wire | Press release

Share
Samsung Expands Advanced 0.7μm-Pixel ISOCELL Image Sensor Offerings for Wider Mobile Applications

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced four new Samsung ISOCELL image sensors for its 0.7 micrometer (μm)-pixel product lineup; 108-megapixel (Mp) ISOCELL HM2, 64Mp ISOCELL GW3, 48Mp ISOCELL GM5 and 32Mp ISOCELL JD1. With the new 0.7μm ISOCELL technology, Samsung plans to expand the ultra-high-resolution offerings to mainstream smartphones.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005521/en/

“Samsung continues to pioneer innovations, such as ISOCELL Plus and Smart ISO, to deliver more pixels in a smaller package,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “Last year, Samsung introduced the industry’s first 0.7μm-pixel image sensor and the first 108Mp sensors. Now we are bringing more of the advanced pixel technologies to mobile cameras in a variety of options that will enable high-resolution images and sleeker designs in a wider selection of tomorrow’s mobile devices.”

For ultra-high-resolution image sensors, even a mere 0.1μm-difference per pixel can have a significant impact on the overall size of the sensor as well as the height of the camera module. With pixels at 0.7μm, Samsung’s newest image sensors are up to 15-percent smaller than the 0.8μm sensors of the same resolution and reduce the height of the camera module by up to 10 percent. Smaller form factors give smartphone manufacturers more flexibility, such as added features or more streamlined designs, when developing their next-generation devices.

To collect an ample amount of light and increase the full well capacity despite the minute pixel sizes, Samsung has incorporated its advanced ISOCELL Plus and Smart-ISO technologies, especially optimized for 0.7μm. ISOCELL Plus retains the received light with a wall-like structure around the pixel while Smart-ISO makes full use of the incoming light by intelligently adjusting the ISO accordingly for optimal exposure.

In the latest 0.7μm products to be introduced later this year, Samsung will start rolling out an enhanced pixel technology, ISOCELL 2.0, which allows excellent performance despite the challenges with decreasing pixel sizes. The new technology further enhanced the wall structure between cells, resulting in added light sensitivity of up to 12 percent compared to the current ISOCELL Plus technology.

The New 0.7μm Lineup;

  1. ISOCELL HM2 is Samsung’s third 108Mp image sensor following the HMX and HM1. The new 108Mp-sensor is around 15-percent smaller than the 0.8μm-based predecessors, and reduces the height of the camera module by 10 percent. The HM2 features Super PD, a faster and more effective phase detecting auto focus solution, and like the HM1, comes with a nine-pixel binning technology as well as 3x lossless zoom.
  2. ISOCELL GW3 is a 64Mp-image sensor optimized for mainstream devices. Thanks to the smaller pixel size, the GW3’s optical size is nearly identical to that of Samsung’s 0.8μm 48Mp image sensor. In addition to Tetracell and Smart-ISO technologies that help the sensor take bright images with high color fidelity, the GW3 is ideal for active lifestyles, featuring gyro-based electronic image stabilization (EIS) for sharper still photos and steadier videos. The image sensor supports video recording at up to 4K resolution at 60 frames-per-second (fps).
  3. ISOCELL GM5 is a versatile 48Mp-image sensor designed for use in telescoping or ultra-wide angle cameras. When used as a 5x optical telescoping sensor for folded-zoom, the GM5 takes full advantage of the compact 0.7μm pixel size that minimizes the camera bulge. For ultra-wide shots, the GM5 supports high-speed full-HD recording at 480fps. The sensor also offers a staggered-HDR feature, a faster and more power-efficient HDR technology that expedites image processing by sending a readout of long, medium, and short exposures of each row of pixels respectively to the mobile processor. As the readout is performed based on Tetracell’s 1.4μm two-by-two pixels, rather than at the individual 0.7μm-pixel level, staggered-HDR can provide brighter and clearer images with less noise.
  4. ISOCELL JD1 is the industry’s smallest 32Mp-image sensor at 1/3.14-inches, making it an ideal solution for smartphones with bezel-less displays that incorporate a hole-in-active-area or motorized pop-up mechanism for the front-facing camera. Even with 32-million pixels to capture a highly detailed selfie, the camera sits comfortably under the display as the height of the sensor’s camera module is comparable to those of 0.9μm 20Mp or 1.0μm 16Mp sensors. Like the GM5, the JD1 is also the one the first ISOCELL image sensors to offer staggered-HDR.

Samsung ISOCELL HM2, GW3 and JD1 are currently in mass production, and the company is sampling GM5.

# # #

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye